Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 555

1.

Clinical Features and Outcome of Hepatosplenic Fungal Infections in Children with Hematological Malignancies.

Madney Y, Hafez H, Elanany M, Adel N, Nasr E, Alsheshtawi K, Younes A, Shalaby L.

Mycoses. 2019 Sep 12. doi: 10.1111/myc.13002. [Epub ahead of print]

PMID:
31514231
2.

Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy.

Menon H, Chen D, Ramapriyan R, Verma V, Barsoumian HB, Cushman TR, Younes AI, Cortez MA, Erasmus JJ, de Groot P, Carter BW, Hong DS, Glitza IC, Ferrarotto R, Altan M, Diab A, Chun SG, Heymach JV, Tang C, Nguyen QN, Welsh JW.

J Immunother Cancer. 2019 Sep 4;7(1):237. doi: 10.1186/s40425-019-0718-6.

3.

The application of poorly crystalline silicotitanate in production of 225Ac.

Fitzsimmons J, Abraham A, Catalano D, Younes A, Cutler CS, Medvedev D.

Sci Rep. 2019 Aug 14;9(1):11808. doi: 10.1038/s41598-019-48021-7.

4.

Reply to M. Skelin et al.

Wilson WH, Staudt L, Younes A.

J Clin Oncol. 2019 Aug 7:JCO1901603. doi: 10.1200/JCO.19.01603. [Epub ahead of print] No abstract available.

PMID:
31390273
5.

Efficacy of platelet-rich plasma plus fractional carbon dioxide laser in treating posttraumatic scars.

Makki M, Younes AEKH, Fathy A, Abd ElDayem OY, Morsy H.

Dermatol Ther. 2019 Jul 25:e13031. doi: 10.1111/dth.13031. [Epub ahead of print]

PMID:
31344305
6.

Will GALEN become more RELEVANT?

von Keudell G, Younes A.

Lancet Haematol. 2019 Aug;6(8):e391-e392. doi: 10.1016/S2352-3026(19)30136-X. Epub 2019 Jul 8. No abstract available.

PMID:
31296424
7.

Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO.

Bhupathiraju NVSDK, Younes A, Cao M, Ali J, Cicek HT, Tully KM, Ponnala S, Babich JW, Deri MA, Lewis JS, Francesconi LC, Drain CM.

Org Biomol Chem. 2019 Jul 17;17(28):6866-6871. doi: 10.1039/c9ob01068h.

PMID:
31268109
8.

Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.

Wang S, Mondal S, Zhao C, Berishaj M, Ghanakota P, Batlevi CL, Dogan A, Seshan VE, Abel R, Green MR, Younes A, Wendel HG.

JCI Insight. 2019 Jun 20;4(12). pii: 127566. doi: 10.1172/jci.insight.127566. eCollection 2019 Jun 20.

9.

Magnetically modified hydroxyapatite nanoparticles for the removal of uranium (VI): Preparation, characterization and adsorption optimization.

El-Maghrabi HH, Younes AA, Salem AR, Rabie K, El-Shereafy ES.

J Hazard Mater. 2019 May 30;378:120703. doi: 10.1016/j.jhazmat.2019.05.096. [Epub ahead of print]

PMID:
31203125
10.

New drugs for new targets in lymphoma.

Younes A.

Hematol Oncol. 2019 Jun;37 Suppl 1:105-109. doi: 10.1002/hon.2592. Review. No abstract available.

PMID:
31187529
11.

Added predictive value of 18F-FDG PET/CT for pediatric rhabdomyosarcoma.

El-Kholy E, El Nadi E, Hafez H, Ahmed S, Younes A, El-Kenanii N, Khalid E.

Nucl Med Commun. 2019 Sep;40(9):898-904. doi: 10.1097/MNM.0000000000001040.

PMID:
31145205
12.

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse.

Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, Palomba MLM, Portlock C, Straus DJ, Noy A, Horwitz SM, Moskowitz A, Hamlin P, Moskowitz CH, Matasar MJ, Zelenetz AD, Younes A.

Blood Cancer J. 2019 May 20;9(6):50. doi: 10.1038/s41408-019-0209-5.

13.

Stability After Initial Decline in Coronary Revascularization Rates in the United States.

Raza S, Deo SV, Kalra A, Zia A, Altarabsheh SE, Deo VS, Mustafa RR, Younes A, Rao SV, Markowitz AH, Park SJ, Costa MA, Simon DI, Bhatt DL, Sabik JF 3rd.

Ann Thorac Surg. 2019 Apr 27. pii: S0003-4975(19)30596-X. doi: 10.1016/j.athoracsur.2019.03.080. [Epub ahead of print]

PMID:
31039350
14.

Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma.

Kumar A, Ying Z, Alperovich A, Dogan A, Hamlin P, Moskowitz C, Pichardo J, Portlock C, Sha F, Zelenetz AD, Zhang Z, Drill E, Woo K, Younes A.

Haematologica. 2019 Apr;104(4):e163-e166. doi: 10.3324/haematol.2018.201350. No abstract available.

15.

IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

Li A, Barsoumian HB, Schoenhals JE, Caetano MS, Wang X, Menon H, Valdecanas DR, Niknam S, Younes AI, Cortez MA, Welsh JW.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):903-912. doi: 10.1016/j.ijrobp.2019.03.022. Epub 2019 Mar 21.

PMID:
30905636
16.

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D, Samoilova O, Suh C, Leppä S, Rai S, Turgut M, Jurczak W, Cheung MC, Gurion R, Yeh SP, Lopez-Hernandez A, Dührsen U, Thieblemont C, Chiattone CS, Balasubramanian S, Carey J, Liu G, Shreeve SM, Sun S, Zhuang SH, Vermeulen J, Staudt LM, Wilson W; PHOENIX investigators.

J Clin Oncol. 2019 May 20;37(15):1285-1295. doi: 10.1200/JCO.18.02403. Epub 2019 Mar 22.

17.

Corrigendum to 'Surgery in perforated pediatric intestinal lymphoma' [European Journal of Surgical Oncology 45 (2019) 279-283].

Ahmed G, ElShafiey M, Abdelrahman H, Semary S, Elkinaai N, Romeih M, Mohy R, Younes A.

Eur J Surg Oncol. 2019 May;45(5):928. doi: 10.1016/j.ejso.2019.02.024. Epub 2019 Mar 7. No abstract available.

PMID:
30853169
18.

Emerging epigenetic-modulating therapies in lymphoma.

Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A.

Nat Rev Clin Oncol. 2019 Aug;16(8):494-507. doi: 10.1038/s41571-019-0190-8. Review.

19.

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.

Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F.

Br J Haematol. 2019 May;185(4):670-678. doi: 10.1111/bjh.15814. Epub 2019 Feb 28.

PMID:
30820940
20.

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.

Borchmann S, Joffe E, Moskowitz CH, Zelenetz AD, Noy A, Portlock CS, Gerecitano JF, Batlevi CL, Caron PC, Drullinsky P, Hamilton A, Hamlin PA Jr, Horwitz SM, Kumar A, Matasar MJ, Moskowitz AJ, Owens CN, Palomba ML, Younes A, Straus DJ.

Blood. 2019 May 16;133(20):2121-2129. doi: 10.1182/blood-2018-10-877761. Epub 2019 Feb 15.

PMID:
30770396
21.

Structured Crowdsourcing Enables Convolutional Segmentation of Histology Images.

Amgad M, Elfandy H, Khallaf HH, Atteya LA, Elsebaie MAT, Elnasr LSA, Sakr RA, Salem HSE, Ismail AF, Saad AM, Ahmed J, Elsebaie MAT, Rahman M, Ruhban IA, Elgazar NM, Alagha Y, Osman MH, Alhusseiny AM, Khalaf MM, Younes AF, Abdulkarim A, Younes DM, Gadallah AM, Elkashash AM, Fala SY, Zaki BM, Beezley J, Chittajallu DR, Manthey D, Gutman DA, Cooper LAD.

Bioinformatics. 2019 Feb 6. doi: 10.1093/bioinformatics/btz083. [Epub ahead of print]

PMID:
30726865
22.

Is hydroxypyridonate 3,4,3-LI(1,2-HOPO) a good competitor of fetuin for uranyl metabolism?

Younes A, Creff G, Beccia MR, Moisy P, Roques J, Aupiais J, Hennig C, Solari PL, Den Auwer C, Vidaud C.

Metallomics. 2019 Feb 20;11(2):496-507. doi: 10.1039/c8mt00272j.

PMID:
30644488
23.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W.

Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.

PMID:
30642819
24.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.

Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ.

Clin Cancer Res. 2019 Mar 15;25(6):1718-1726. doi: 10.1158/1078-0432.CCR-18-2435. Epub 2019 Jan 7.

PMID:
30617130
25.

Appropriate use criteria adoption for PCI at an academic medical center.

Younes A, Hoff JS, Bojansky AM, Kalra A.

Eur Heart J. 2018 Dec 14;39(47):4136-4138. doi: 10.1093/eurheartj/ehy756. No abstract available.

PMID:
30551141
26.

Seroprevalence, isolation, molecular detection and genetic diversity of Toxoplasma gondii from small ruminants in Egypt.

Abd El-Razik KA, Barakat AMA, Hussein HA, Younes AM, Elfadaly HA, Eldebaky HA, Soliman YA.

J Parasit Dis. 2018 Dec;42(4):527-536. doi: 10.1007/s12639-018-1029-4. Epub 2018 Oct 15.

PMID:
30538350
27.

Novel therapeutic agents for relapsed classical Hodgkin lymphoma.

von Keudell G, Younes A.

Br J Haematol. 2019 Jan;184(1):105-112. doi: 10.1111/bjh.15695. Epub 2018 Dec 11. Review.

PMID:
30536386
28.

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.

Umakanthan JM, Iqbal J, Batlevi CL, Bouska A, Smith LM, Shostrom V, Nutsch H, William BM, Gregory Bociek R, Lunning M, Bierman P, Younes A, Armitage JO, Vose JM.

Br J Haematol. 2019 Mar;184(5):744-752. doi: 10.1111/bjh.15702. Epub 2018 Dec 5.

PMID:
30520026
29.

Endovascular Embolization of Post-tonsillectomy Pseudoaneurysm: A Single-Center Case Series.

Hassan F, Younes A, Rifai M.

Cardiovasc Intervent Radiol. 2019 Apr;42(4):528-533. doi: 10.1007/s00270-018-2131-9. Epub 2018 Dec 5.

PMID:
30519726
30.

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS.

J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5.

31.

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.

Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A.

JCI Insight. 2018 Nov 15;3(22). pii: 125568. doi: 10.1172/jci.insight.125568. No abstract available.

32.

Excitation-Dependent Multiple Fluorescence of a Substituted 2-(2'-Hydroxyphenyl)benzoxazole.

Meisner QJ, Younes AH, Yuan Z, Sreenath K, Hurley JJM, Zhu L.

J Phys Chem A. 2018 Nov 29;122(47):9209-9223. doi: 10.1021/acs.jpca.8b07988. Epub 2018 Nov 15.

PMID:
30411891
33.

NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death.

Liu Y, Mondello P, Erazo T, Tannan NB, Asgari Z, de Stanchina E, Nanjangud G, Seshan VE, Wang S, Wendel HG, Younes A.

Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):12034-12039. doi: 10.1073/pnas.1806928115. Epub 2018 Nov 7.

34.

Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.

Nafee T, Gibson CM, Yee MK, Alkhalfan F, Chi G, Travis R, Mir M, Kalayci A, Jafarizade M, Ganti A, Kazmi SH, Ghaffarpasand E, Pitliya A, Datta S, Sharfaei S, Alihashemi M, Elsaiey A, Qamar I, Jahansouz M, Talib U, Kahe F, Habibi S, Abdelwahed M, Tariq F, Kaur M, Younes A, Walia SS, Singh A, Dildar SM, Afzal MK, Kerneis M.

Expert Rev Cardiovasc Ther. 2018 Nov;16(11):845-855. doi: 10.1080/14779072.2018.1534068. Epub 2018 Oct 15. Review.

PMID:
30296387
35.

Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.

Schoenhals JE, Cushman TR, Barsoumian HB, Li A, Cadena AP, Niknam S, Younes AI, Caetano MDS, Cortez MA, Welsh JW.

Front Immunol. 2018 Sep 20;9:2170. doi: 10.3389/fimmu.2018.02170. eCollection 2018.

36.

Surgery in perforated pediatric intestinal lymphoma.

Ahmed G, ElShafiey M, Abdelrahman H, Semary S, Elkinaai N, Romeih M, Mohy R, Younes A.

Eur J Surg Oncol. 2019 Feb;45(2):279-283. doi: 10.1016/j.ejso.2018.08.022. Epub 2018 Sep 6. Erratum in: Eur J Surg Oncol. 2019 May;45(5):928.

PMID:
30224248
37.

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.

Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ.

Haematologica. 2019 Feb;104(2):e65-e67. doi: 10.3324/haematol.2018.199844. Epub 2018 Sep 6. No abstract available.

38.

BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.

Derenzini E, Mondello P, Erazo T, Portelinha A, Liu Y, Scallion M, Asgari Z, Philip J, Hilden P, Valli D, Rossi A, Djaballah H, Ouerfelli O, de Stanchina E, Seshan VE, Hendrickson RC, Younes A.

Cell Rep. 2018 Aug 21;24(8):2155-2166. doi: 10.1016/j.celrep.2018.07.055.

39.

Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab.

Matsuki E, Bohn OL, El Jamal S, Pichardo JD, Zelenetz AD, Younes A, Teruya-Feldstein J.

Appl Immunohistochem Mol Morphol. 2019 Sep;27(8):572-580. doi: 10.1097/PAI.0000000000000645.

PMID:
30106758
40.

Is Polonium-210 a Good Indicator for Anthropogenic Radioactivity?

Younes A, Alliot C, Mokili M, Montavon G.

Cancer Biother Radiopharm. 2018 Oct;33(8):356-360. doi: 10.1089/cbr.2018.2496. Epub 2018 Aug 8.

PMID:
30088970
41.

Phytochemical Screening and Antidiabetic, Antihyperlipidemic, and Antioxidant Properties of Anthyllis henoniana (Coss.) Flowers Extracts in an Alloxan-Induced Rats Model of Diabetes.

Ben Younes A, Ben Salem M, El Abed H, Jarraya R.

Evid Based Complement Alternat Med. 2018 Jun 24;2018:8516302. doi: 10.1155/2018/8516302. eCollection 2018.

42.

Genetic diversity and population structure of local and exotic sheep breeds in Jordan using microsatellites markers.

Jawasreh KI, Ababneh MM, Ismail ZB, Younes AMB, Sukhni IA.

Vet World. 2018 Jun;11(6):778-781. doi: 10.14202/vetworld.2018.778-781. Epub 2018 Jun 9.

43.

Surrogate end points in lymphoma.

Batlevi CL, Younes A.

Ann Oncol. 2018 Aug 1;29(8):1622-1623. doi: 10.1093/annonc/mdy219. No abstract available.

PMID:
29905757
44.

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.

Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A.

Blood Cancer J. 2018 Jun 12;8(6):60. doi: 10.1038/s41408-018-0089-0.

45.

Visual Diagnosis: Syncopal Episode in a 14-year-old Adolescent Boy.

Younes A, Ekeruo IA, Evangelista MS.

Pediatr Rev. 2018 Jun;39(6):e27-e30. doi: 10.1542/pir.2016-0150. No abstract available.

PMID:
29858302
46.

Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.

Niknam S, Barsoumian HB, Schoenhals JE, Jackson HL, Yanamandra N, Caetano MS, Li A, Younes AI, Cadena A, Cushman TR, Chang JY, Nguyen QN, Gomez DR, Diab A, Heymach JV, Hwu P, Cortez MA, Welsh JW.

Clin Cancer Res. 2018 Nov 15;24(22):5735-5743. doi: 10.1158/1078-0432.CCR-17-3279. Epub 2018 May 21.

47.

Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.

Li A, Barsoumian HB, Schoenhals JE, Cushman TR, Caetano MS, Wang X, Valdecanas DR, Niknam S, Younes AI, Li G, Woodward WA, Cortez MA, Welsh JW.

Cancer Lett. 2018 Sep 1;431:54-63. doi: 10.1016/j.canlet.2018.05.005. Epub 2018 May 8.

48.

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A.

Cancer. 2018 Jun 15;124(12):2561-2569. doi: 10.1002/cncr.31361. Epub 2018 May 3.

49.

First experience of the Egyptian National Cancer Institute using the robot-assisted laparoscopic approach in radical hysterectomies for cervical cancer.

Zaghloul AS, El-Minawi AM, ElKordy MA, Younes AK, Mahmoud AM, Fadlalla WM, Mohamed GA.

J Egypt Natl Canc Inst. 2018 Jun;30(2):61-67. doi: 10.1016/j.jnci.2018.03.003.

50.

Low-grade chronic inflammation mediated by mast cells in fibromyalgia: role of IL-37.

Mastrangelo F, Frydas I, Ronconi G, Kritas SK, Tettamanti L, Caraffa Al, D Ovidio C, Younes A, Gallenga CE, Conti P.

J Biol Regul Homeost Agents. 2018 Mar-Apr;32(2):195-198.

PMID:
29684996

Supplemental Content

Loading ...
Support Center